Interestingly, EGFR was found to interact with c-MET and phosphorylate PARP-Y907 in the HCC cells that have high EGFR and c-MET expression, and simultaneous inhibition of both EGFR and c-MET significantly increases the anti-tumor activity of PARPi in such HCC cells [111]. Here, EGFR is linked to hepatocellular carcinoma.